In a matter of months, cancer researchers have gone from grappling with a surge of COVID-19 with limited clinical data to playing a critical role in the development of successful mRNA vaccines against the disease.
Imagine a future where cancer patients are able to receive the treatment they precisely need and not the treatment that is prescribed to all.
FDA has granted accelerated approval to Ukoniq (umbralisib), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications:
FDA has approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma
FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma previously treated with an hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics In care collaborating to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents, which target two of the most frequent KRAS mutations in cancer.
The European Commission has granted full marketing authorization to Inrebic (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase inhibitor naïve or have been treated with ruxolitinib.
ASCO, Friends of Cancer Research recommend broadening eligibility criteria in cancer clinical trials
The American Society of Clinical Oncology and Friends of Cancer Research jointly issued recommendations to broaden eligibility criteria in cancer clinical trials, with the goal of making clinical trials more accessible to patients.
Rice University researchers have discovered a genome editing tool that targets the supporting players in a cell's nucleus that package DNA and aid gene expression.
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.
